This big change is a really good thing for keeping people safe
Leading Companies Intensify Innovation and Capacity Expansion: Competition within the GLP-1 receptor agonist market is increasing with companies producing more product, getting more approvals, making an effort in the oral formulation, developing the next generation receptor agonist, and developing the pipeline for biosimilars
In certain instances, once exposure to an active agent (e.g., concentration in the endolymph or perilymph) reaches steady state, the concentration of an active agent in the endolymph or perilymph stays at or about the therapeutic dose for an extended period of time (e.g., one day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 3 weeks, 6 weeks, or 2 months)
Is this compounded with base form or salt form
Freeman Cyanocobalamin a case for withdrawal: discussion paper